Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Blood Transfus ; 14(2): 199-205, 2016 05.
Artigo em Inglês | MEDLINE | ID: mdl-27177405

RESUMO

BACKGROUND: Anaemia and iron deficiency are very common in inflammatory bowel disease. Clinical trials have shown intravenous iron to be effective and well tolerated. However, published experience in clinical practice with specific evaluation of the effect on quality of life is limited. MATERIAL AND METHODS: We carried out a prospective, multicentre, observational study on the effects of ferric carboxymaltose in the treatment of iron deficiency anaemia in inflammatory bowel disease. Anaemia and iron deficiency were defined according to World Health Organization criteria. Efficacy and safety were evaluated at infusion, at 2 weeks and at 12 weeks. Quality of life was evaluated according to the SIBDQ-9 index. Complete response was defined as anaemia correction or more tan 2 g/dL increase in haemoglobin. RESULTS: A total of 88 courses of ferric carboxymaltose in 72 patients were evaluated. Complete response was observed in 46% of patients at week 2, and 81.2% at week 12. Quality of life improved significatively at week 2 in both complete responders and partial responders (p<0.0005); complete responders showed siginficantly better response (p=0.016). No predictive factor was identified. Only one transient adverse effect was observed; however, this was severe. DISCUSSION: Ferric carboxymaltose showed comparable efficacy to that demonstrated in clinical trials. After only two weeks of treatment, there was a significant improvement in quality of life, with a greater effect observed in those patients with a complete haematologic response. Intravenous iron can very quickly improve quality of life in inflammatory bowel disease.


Assuntos
Anemia Ferropriva/complicações , Anemia Ferropriva/tratamento farmacológico , Compostos Férricos/uso terapêutico , Doenças Inflamatórias Intestinais/complicações , Maltose/análogos & derivados , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Compostos Férricos/efeitos adversos , Humanos , Masculino , Maltose/efeitos adversos , Maltose/uso terapêutico , Pessoa de Meia-Idade , Estudos Prospectivos , Qualidade de Vida , Adulto Jovem
2.
Clín. investig. arterioscler. (Ed. impr.) ; 26(5): 218-223, sept.-oct. 2014. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-128502

RESUMO

Objetivos Este estudio se diseñó para establecer la correlación entre la concentración de lipoproteína(a) [Lp(a)], apolipoproteínas y lípidos con los parámetros bioquímicos de función hepática en un grupo de pacientes con colestasis reversible, así como la concentración de estos parámetros una vez resuelto el proceso de obstrucción biliar. Material y métodos Se incluyeron en el estudio de forma prospectiva 18 adultos mayores de 17 años con colestasis extrahepática y se determinaron los parámetros de función hepática, así como los parámetros del metabolismo lipídico y lipoproteico, especialmente Lp(a) antes y después de la desobstrucción. Resultados La concentración de Lp(a) previa a la desobstrucción se correlacionó inversamente de forma estadísticamente significativa con la concentración de gamma glutamil transpeptidasa (coeficiente de correlación [r] = -0,757; p = 0,018). La concentración de Lp(a) (mediana = 2,66 mg/dl; rango intercuartílico = 5,62) se elevó de forma estadísticamente significativa tras la desobstrucción (mediana = 9,72 mg/dl; rango intercuartílico = 28,76; p = 0,001). Hubo descensos estadísticamente significativos tras la desobstrucción en las concentraciones de colesterol total y triglicéridos y ascensos estadísticamente significativos en colesterol HDL y apolipoproteína A-1. Conclusiones: La concentración de Lp(a) se encuentra disminuida durante la colestasis, a pesar de existir una importante hipercolesterolemia simultánea. La colestasis ejerce un papel causal en el descenso de Lp(a), ya que la desobstrucción de la vía biliar recupera las concentraciones de Lp(a). Nuestro estudio apoya el concepto de que los ácidos biliares ejercen un efecto represor en la síntesis de Lp(a) y abre un mecanismo para el tratamiento de la hiper Lp(a)


Objectives: This study was appointed to determine the correlation between the concentration of lipoprotein(a) [Lp(a)], apolipoproteins and lipids with biochemical parameters of liver function in a group of patients with reversible cholestasis. We have also determined the concentration of these parameters once solved the biliary obstruction process. Material and methods: Eighteen adults over 17 years with extrahepatic cholestasis were included in the study on a prospective basis, and we determined in them biochemical liver function parameters and lipoprotein metabolism parameters, particularly Lp(a) before and after unblocking. Results: The concentration of Lp(a) prior to desobstruction was inverse and statistically significantly correlated with the concentration of gamma glutamyl transpeptidase (correlation coefficient [r] = -0.757, P = .018). The concentration of Lp(a) (median = 2.66 mg/dL, interquartile range = 5,62) showed a statistically significant increase (median = 9.72 mg/dL, interquartile range = 28.76, P < .001), once the unblocking was performed. Concentrations of total cholesterol and triglycerides had a statistically significant decrease, and HDL cholesterol and apolipoproteinA-1 showed a statistically significant increase once the unblocking was carried out. Conclusions: The concentration of Lp(a) is decreased during cholestasis, although there is a significant simultaneous hypercholesterolemia. Cholestasis has a causal role in lowering Lp(a), because the unblocking of bile duct recovers Lp(a) concentration. Our study supports the concept that bile acids exert a controlling effect on the synthesis of Lp(a) and open a mechanism for the treatment of hyper Lp(a)


Assuntos
Humanos , Lipoproteínas , Colestase/fisiopatologia , Apolipoproteínas , Lipídeos , Ácidos e Sais Biliares/análise , Estudos Prospectivos
3.
Clin Investig Arterioscler ; 26(5): 218-23, 2014.
Artigo em Espanhol | MEDLINE | ID: mdl-24629889

RESUMO

OBJECTIVES: This study was appointed to determine the correlation between the concentration of lipoprotein(a) [Lp(a)], apolipoproteins and lipids with biochemical parameters of liver function in a group of patients with reversible cholestasis. We have also determined the concentration of these parameters once solved the biliary obstruction process. MATERIAL AND METHODS: Eighteen adults over 17 years with extrahepatic cholestasis were included in the study on a prospective basis, and we determined in them biochemical liver function parameters and lipoprotein metabolism parameters, particularly Lp(a) before and after unblocking. RESULTS: The concentration of Lp(a) prior to desobstruction was inverse and statistically significantly correlated with the concentration of gamma glutamyl transpeptidase (correlation coefficient [r] = -0.757, P = .018). The concentration of Lp(a) (median = 2.66 mg/dL, interquartile range = 5,62) showed a statistically significant increase (median = 9.72 mg/dL, interquartile range = 28.76, P < .001), once the unblocking was performed. Concentrations of total cholesterol and triglycerides had a statistically significant decrease, and HDL cholesterol and apolipoprotein A-1 showed a statistically significant increase once the unblocking was carried out. CONCLUSIONS: The concentration of Lp(a) is decreased during cholestasis, although there is a significant simultaneous hypercholesterolemia. Cholestasis has a causal role in lowering Lp(a), because the unblocking of bile duct recovers Lp(a) concentration. Our study supports the concept that bile acids exert a controlling effect on the synthesis of Lp(a) and open a mechanism for the treatment of hyper Lp(a).


Assuntos
Colestase Extra-Hepática/fisiopatologia , Hipercolesterolemia/epidemiologia , Lipoproteína(a)/metabolismo , gama-Glutamiltransferase/metabolismo , Adulto , Apolipoproteínas/metabolismo , Colestase Extra-Hepática/terapia , Colesterol/sangue , HDL-Colesterol/sangue , Humanos , Hipercolesterolemia/etiologia , Lipídeos/sangue , Testes de Função Hepática , Estudos Prospectivos , Triglicerídeos/sangue
4.
Biomed Res Int ; 2013: 370582, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23841067

RESUMO

Managing bowel obstruction produced by colon cancer requires an emergency intervention to patients usually in poor conditions, and it requires creating an intestinal stoma in most cases. Regardless of that the tumor may be resectable, a two-stage surgery is mandatory. To avoid these disadvantages, endoscopic placement of self-expanding stents has been introduced more than 10 years ago, as an alternative to relieve colonic obstruction. It can be used as a bridge to elective single-stage surgery avoiding a stoma or as a definitive palliative solution in patients with irresectable tumor or poor estimated survival. Stents must be capable of exerting an adequate radial pressure on the stenosed wall, keeping in mind that stent must not move or be crushed, guaranteeing an adequate lumen when affected by peristaltic waves. A finite element simulation of bell-shaped nitinol stent functionality has been done. Catheter introduction, releasing at position, and the effect of peristaltic wave were simulated. To check the reliability of the simulation, a clinical experimentation with porcine specimens was carried out. The stent presented a good deployment and flexibility. Stent behavior was excellent, expanding from the very narrow lumen corresponding to the maximum peristaltic pressure to the complete recovery of operative lumen when the pressure disappears.


Assuntos
Neoplasias do Colo/patologia , Endoscopia do Sistema Digestório/instrumentação , Obstrução Intestinal/patologia , Stents , Adulto , Animais , Doença de Bowen , Neoplasias do Colo/complicações , Neoplasias do Colo/cirurgia , Endoscopia do Sistema Digestório/métodos , Feminino , Humanos , Obstrução Intestinal/complicações , Obstrução Intestinal/cirurgia , Masculino , Pessoa de Meia-Idade , Cuidados Paliativos , Peristaltismo/fisiologia
5.
Am J Gastroenterol ; 100(8): 1685-93, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16086703

RESUMO

BACKGROUND: The worst outcome of gastrointestinal complications is death. Data regarding those associated with nonsteroidal antiinflammatory drug (NSAID) or aspirin use are scarce. AIM: To determine mortality associated with hospital admission due to major gastrointestinal (GI) events and NSAID/aspirin use. METHODS: The study was based on actual count of deaths from two different data sets from 2001. Study 1 was carried out in 26 general hospitals serving 7,901,198 people. Study 2 used a database from 197 general hospitals, representative of the 269 hospitals in the Spanish National Health System. Information regarding gastrointestinal complications and deaths was obtained throughout the Minimum Basic Data Set (CIE-9-MC) provided by participating hospitals. Deaths attributed to NSAID/aspirin use were estimated on the basis of prospectively collected data from hospitals of study 1. RESULTS: The incidence of hospital admission due to major GI events of the entire (upper and lower) gastrointestinal tract was 121.9 events/100,000 persons/year, but those related to the upper GI tract were six times more frequent. Mortality rate was 5.57% (95% CI = 4.9-6.7), and 5.62% (95% CI = 4.8-6.8) in study 1 and study 2, respectively. Death rate attributed to NSAID/aspirin use was between 21.0 and 24.8 cases/million people, respectively, or 15.3 deaths/100,000 NSAID/aspirin users. Up to one-third of all NSAID/aspirin deaths can be attributed to low-dose aspirin use. CONCLUSION: Mortality rates associated with either major upper or lower GI events are similar but upper GI events were more frequent. Deaths attributed to NSAID/ASA use were high but previous reports may have provided an overestimate and one-third of them can be due to low-dose aspirin use.


Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Gastroenteropatias/induzido quimicamente , Gastroenteropatias/mortalidade , Hospitalização/estatística & dados numéricos , Idoso , Aspirina/efeitos adversos , Feminino , Gastroenteropatias/epidemiologia , Hemorragia Gastrointestinal/mortalidade , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Espanha/epidemiologia
6.
Eur J Gastroenterol Hepatol ; 15(2): 173-8, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12560762

RESUMO

OBJECTIVE: To evaluate the risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drug therapy, common analgesics and individual nonsteroidal anti-inflammatory drugs (NSAIDs). METHODS: The case group was made up of 1122 consecutive patients admitted with bleeding from a peptic lesion. The 2231 control subjects consisted of 1109 patients hospitalized for other reasons and 1122 outpatients from the same geographical area. The relative risk was calculated by unconditional logistic regression after adjusting for confounding factors. RESULTS: The use of the antiplatelet agent triflusal, and other commonly used cardiovascular drugs, such as beta-receptor blockers and calcium channel blockers, was not associated with increased risk of upper gastrointestinal bleeding. The use of angiotensin-converting enzyme inhibitors reduced the risk of bleeding by 30% (odds ratio 0.7; 95% confidence interval 0.5-0.96). Use of ketorolac (odds ratio 59.4; 95% confidence interval 7.7-454) and piroxicam (odds ratio 19.6; 95% confidence interval 9.3-35.3) carried the highest risk. Use of paracetamol and tramadol was not associated with increased risk of bleeding, but the non-narcotic agent metamizol was associated with a small increase in risk of upper gastrointestinal bleeding (odds ratio 2.6; 95% confidence interval 1.3-5.2). CONCLUSIONS: The use of the antiplatelet agent triflusal and other cardiovascular drugs apart from low-dose aspirin was not associated with gastrointestinal bleeding. The use of either NSAIDs or aspirin increased the risk of gastrointestinal bleeding but, among the analgesics, only metamizol induced a small increase in the risk of gastrointestinal bleeding.


Assuntos
Analgésicos/efeitos adversos , Anti-Inflamatórios não Esteroides/efeitos adversos , Fármacos Cardiovasculares/efeitos adversos , Hemorragia Gastrointestinal/induzido quimicamente , Idoso , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Bloqueadores dos Canais de Cálcio/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/efeitos adversos , Estudos Prospectivos , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...